Imatinib is a selective multi-kinase inhibitor that targets BCR-ABL, KIT and PDGFR and is an FDA-approved drug to treat chronic myeloid leukemia. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.